- Home
- JXG vs GNPX Comparison
JXG vs GNPX Comparison
Compare JXG & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXG
- GNPX
- Stock Information
- Founded
- JXG N/A
- GNPX 2009
- Country
- JXG China
- GNPX United States
- Employees
- JXG N/A
- GNPX N/A
- Industry
- JXG
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- JXG
- GNPX Health Care
- Exchange
- JXG Nasdaq
- GNPX Nasdaq
- Market Cap
- JXG 4.7M
- GNPX 5.5M
- IPO Year
- JXG N/A
- GNPX 2018
- Fundamental
- Price
- JXG $0.94
- GNPX $0.25
- Analyst Decision
- JXG
- GNPX
- Analyst Count
- JXG 0
- GNPX 0
- Target Price
- JXG N/A
- GNPX N/A
- AVG Volume (30 Days)
- JXG 118.3K
- GNPX 13.6M
- Earning Date
- JXG 05-15-2025
- GNPX 08-14-2025
- Dividend Yield
- JXG N/A
- GNPX N/A
- EPS Growth
- JXG N/A
- GNPX N/A
- EPS
- JXG 0.86
- GNPX N/A
- Revenue
- JXG $49,840,288.00
- GNPX N/A
- Revenue This Year
- JXG N/A
- GNPX N/A
- Revenue Next Year
- JXG N/A
- GNPX N/A
- P/E Ratio
- JXG $1.06
- GNPX N/A
- Revenue Growth
- JXG 56.53
- GNPX N/A
- 52 Week Low
- JXG $0.55
- GNPX $0.14
- 52 Week High
- JXG $8.40
- GNPX $3.97
- Technical
- Relative Strength Index (RSI)
- JXG 37.93
- GNPX 62.04
- Support Level
- JXG $0.85
- GNPX $0.15
- Resistance Level
- JXG $1.04
- GNPX $0.17
- Average True Range (ATR)
- JXG 0.08
- GNPX 0.04
- MACD
- JXG 0.01
- GNPX 0.01
- Stochastic Oscillator
- JXG 39.33
- GNPX 40.19
About JXG JX Luxventure Limited Common Stock
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.